Policy / Pricing FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results FDAThe U.S.Policy / PricingRead full story pharminent April 13, 2026 (Last updated: April 14, 2026) FDA The U.S. Policy / PricingRead full story Post navigation Previous: USP adds Tamiflu, Trulicity to vulnerable list as upstream analysis reshapes supply concernsNext: Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma Related Stories Policy / Pricing MFN affecting Swiss medicines access, says Interpharma pharminent August 13, 2026 Policy / Pricing Prior Authorization Metrics Provide New Insights into Insurer Practices, but Gaps Remain pharminent August 13, 2026 Policy / Pricing Trump signs order that nearly halves childhood immunisation coverage pharminent August 11, 2026
